Congenital myasthenic syndrome (CMS): drug treatment

Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .

Congenital myasthenic syndrome (CMS): drug treatment. ChAT, Sodium channel, Fast channel, Rapsyn. Fully referenced neurology checklist.

Pyridostigmine: indications

  • ChAT
  • Sodium channel
  • Fast channel
  • Rapsyn

Pyridostigmine: contraindications

Locked: subscribe to see this section.

3,4 diaminopyridine (3,4 DAP): indications

Locked: subscribe to see this section.

3,4 diaminopyridine (3,4 DAP): contraindications

Locked: subscribe to see this section.

Treatment of slow channel

Locked: subscribe to see this section.

Treatment of DOK7

Locked: subscribe to see this section.

References

  1. Spillane J, Beeson DJ, Kullmann DM. Myasthenia and related disorders of the neuromuscular junction. JNNP 2010; 81:850-857.
  2. Bertorini TE. Neuromuscular Disorders: Treatment and Management. Elsevier Philadelphia 2011 p334.
  3. Finlayson S, Beeson D, Palace J. Congenital myasthenic syndrome: an update. Pract Neurol 2013; 13:80-91.
  4. Harper CM, Fukodome T, Engel AG. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 2003; 60:1710-1713.
  5. Peyer AK, Abicht A, Heinimann K, Sinnreich M, Fischer D. Quinine sulfate as a therapeutic option in a patient with slow channel congenital myasthenic syndrome. Neuromuscul Disord 2013; 23:571-574. 
  6. And 1 more. Subscribe to see the full list

Related checklists

Loading...